Brand against brand · semaglutide and tirzepatide
Ozempic vs Mounjaro
From the two FDA labels, read Published by PepVault
Ozempic is semaglutide, a GLP-1 receptor agonist, from Novo Nordisk; Mounjaro is tirzepatide, a GIP and GLP-1 receptor agonist, from Eli Lilly.
FDA approved Ozempic for blood sugar control in adults with type 2 diabetes, and lowering heart and kidney risks in some of them. Mounjaro is approved for blood sugar control in type 2 diabetes from age 10, and lowering heart risk in adults with type 2 diabetes.
Label against label
| Compared | Ozempic | Mounjaro |
|---|---|---|
| Active ingredient | semaglutide | tirzepatide |
| Class | GLP-1 receptor agonist | GIP and GLP-1 receptor agonist |
| Maker | Novo Nordisk | Eli Lilly |
| Approved for | Type 2 diabetes; heart and kidney risk in type 2 diabetes | Type 2 diabetes (adults and children 10 and up); heart risk |
| Forms | Multi-dose pen; Single-dose prefilled syringe; Tablet | Single-dose pen or vial; Multi-dose vial or KwikPen |
| How often | once a week or once a day | once a week |
| Starting dose | 0.25 mg a week (injection); 1.5 mg a day (tablets) | 2.5 mg a week |
| Top dose on the label | 2 mg a week (injection); 9 mg a day (tablets) | 15 mg a week |
| Most reported side effect | Nausea, 20.3% on 1 mg (placebo 6.1%) | Nausea, 18% on 15 mg (placebo 4%) |
| Boxed warning | “RISK OF THYROID C-CELL TUMORS” | “RISK OF THYROID C-CELL TUMORS” |
| First approved | 2017 | 2022 |
Each label’s side-effect figure comes from its own trials, at its own doses and in its own patients; as the labels themselves say, rates from different trials can’t be compared directly.
The two dosing schedules
This is the dosing schedule as the FDA label states it. A prescriber sets the actual dose and when it changes; it is not an instruction to the reader.
Ozempic injection, once a week
Ozempic tablets, once a day
Mounjaro, once a week

A missed dose, on each label
The trial evidence
Questions
What is the difference between Ozempic and Mounjaro?
Ozempic is semaglutide, a GLP-1 receptor agonist; Mounjaro is tirzepatide, a GIP and GLP-1 receptor agonist. Their labels approve them for different uses and set different schedules.
What are Ozempic and Mounjaro approved for?
Ozempic is approved for blood sugar control in adults with type 2 diabetes, and lowering heart and kidney risks in some of them. Mounjaro is approved for blood sugar control in type 2 diabetes from age 10, and lowering heart risk in adults with type 2 diabetes.
How often are Ozempic and Mounjaro taken?
Ozempic is taken once a week or once a day, as an injection or a tablet; Mounjaro once a week, as an injection.
What are the dose ranges of Ozempic and Mounjaro?
On their labels, Ozempic runs 0.25 mg to 2 mg once a week or 1.5 mg to 9 mg once a day, and Mounjaro 2.5 mg to 15 mg once a week. A prescriber sets the actual dose.
What is the most common side effect of Ozempic and Mounjaro?
On Ozempic’s label: nausea, 20.3% on 1 mg (placebo 6.1%). On Mounjaro’s: nausea, 18% on 15 mg (placebo 4%).
Sources
- OZEMPIC (semaglutide) injection, for subcutaneous use, FDA label on DailyMed (version 20, published Jun 10, 2026; read Nov 18, 2026)
- RYBELSUS (semaglutide) tablets and OZEMPIC (semaglutide) tablets, for oral use, FDA label on DailyMed (version 14, published Aug 19, 2026; read Nov 18, 2026)
- MOUNJARO (tirzepatide) injection, for subcutaneous use, FDA label on DailyMed (version 40, published Sep 2, 2026; read Nov 18, 2026)
- Drugs@FDA, NDA 209637 (Ozempic, the injection; application first approved 2017)
- Drugs@FDA, NDA 213051 (Ozempic, the tablets, added to the application by supplement 30 on Jan 30, 2026; application first approved 2019)
- Drugs@FDA, NDA 215866 (Mounjaro, the injection; application first approved 2022)
PepVault is not affiliated with Novo Nordisk. Ozempic is a trademark of its owner. PepVault is not affiliated with Eli Lilly. Mounjaro is a trademark of its owner.